| Date Filed | Type | Description |
| 02/13/2019 |
GN
| New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing — Factors of Influence, Major Initiatives and Sustained Production |
| 12/10/2018 |
GN
| Report: Developing Opportunities within Covanta Holding, Zscaler, Avaya, Seattle Genetics, Viad, and Canada Goose — Future Expectations, Projections Moving into 2019 |
| 06/26/2018 |
GN
| Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Results |
| 05/09/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags Entertainment Corporation New, Leucadia National, Seattle Genetics, and RPC — New Research Emphasizes Economic Growth |
| 04/26/2018 |
BW
| Seattle Genetics Reports First Quarter 2018 Financial Results |
| 04/05/2018 |
BW
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018 |
| 03/13/2018 |
BW
| Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018 |
| 03/07/2018 |
GN
| Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharma, and Dollar General — Future Expectations, Projections Moving into 2018 |
| 02/06/2018 |
BW
| Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results |
| 01/18/2018 |
BW
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018 |
| 12/04/2017 |
BW
| Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting |
| 10/26/2017 |
BW
| Seattle Genetics Reports Third Quarter 2017 Financial Results |
| 07/27/2017 |
BW
| Seattle Genetics Reports Second Quarter 2017 Financial Results |
| 07/06/2017 |
BW
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017 |
| 06/26/2017 |
BW
| Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma |
| 04/27/2017 |
BW
| Seattle Genetics Reports First Quarter 2017 Financial Results |
| 04/06/2017 |
BW
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017 |
| 03/09/2017 |
GN
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017 |
| 03/08/2017 |
GN
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN |
| 03/05/2017 |
GN
| DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact The Firm |
| 03/01/2017 |
BW
| Seattle Genetics to Present at Upcoming Investor Conferences |
| 02/28/2017 |
GN
| IMPORTANT SEATTLE GENETICS INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the Western District of Washington against Seattle Genetics Inc. |
| 02/27/2017 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline – SGEN |
| 02/17/2017 |
GN
| Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer |
| 02/17/2017 |
GN
| Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer |
| 02/15/2017 |
GN
| SGEN NOTICE: Rosen Law Firm Reminds Seattle Genetics Inc. Investors of Important Deadline in Class Action – SGEN |
| 02/09/2017 |
BW
| Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results |
| 02/08/2017 |
GN
| SGEN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Seattle Genetics Inc. and a Lead Plaintiff Deadline of March 13, 2017 |
| 02/03/2017 |
GN
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Seattle Genetics Inc. (SGEN) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit |
| 02/03/2017 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seattle Genetics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – SGEN |
| 01/31/2017 |
GN
| EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Seattle Genetics Inc. – SGEN |
| 01/27/2017 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Seattle Genetics Inc. of Class Action Lawsuit and Upcoming Deadline – SGEN |
| 01/27/2017 |
GN
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Seattle Genetics, Inc. (SGEN) and Lead Plaintiff Deadline: March 13, 2017 |
| 08/19/2011 |
BW
| Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications |
|